The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.
Stefan Kubicka
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche; Sanofi
Roger Von Moos
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche
Honoraria - Amgen; Roche
Research Funding - Roche
Expert Testimony - Amgen
Richard Greil
No relevant relationships to disclose
Javier Sastre
Honoraria - Roche
Research Funding - Roche
Pia J. Osterlund
Consultant or Advisory Role - Roche
Honoraria - Roche
Dirk Arnold
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Roche
Thierry André
Consultant or Advisory Role - Amgen; Roche
Honoraria - Merck; Sanofi
Eric Van Cutsem
Research Funding - Roche
Thomas Mueller
Employment or Leadership Position - Genentech
Irmarie Reyes-Rivera
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Honoraria - Roche
Research Funding - Roche
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Honoraria - Roche